A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
Study Status
Open to Enrollment
Study Description
This clinical trial is for men and women who have been diagnosed with a renal cell tumor, a type of kidney cancer, have had the tumor surgically removed from the kidney, and may have had part or all of a kidney removed. Even though all of the visible tumor may have been completely taken out, very small tumor cells can remain in the body. They can grow and build a new tumor somewhere in the body months or even years later.
The purpose of this study is to determine if the experimental drug pazopanib (also called Votrient) can prevent or delay the renal cell tumor from coming back after the tumor has been surgically removed. The study will also test the safety of pazopanib.
Study participants will be randomly assigned to receive either pazopanib or a placebo (a pill that looks like pazopanib but contains no active drug).
Pazopanib/placebo will be taken every day. Study participation will be up to 5 years, including the study treatment period and follow-up.
Disease Status and/or Stage
Kidney Cancer, Surgically Removed
Sponsor
GlaxoSmithKline
Key Eligibility
- Age 18 and older
- Diagnosis of renal cell carcinoma (RCC)
- Have had complete surgical resection of RCC via nephrectomy
- Detailed eligibility reviewed when you contact the study team
Principal Investigator
Contact
- Renee Kahn, RN
- (212) 746-1851
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]
